Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Size Price Stock Quantity  
In DMSO USD 195 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 35 Publications

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NE\2NFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS0eGhKSzVyPUCuNFAxOzB|IN88US=> NV\tbmVkW0GQR1XS
IST-MEL1 NWjOR5FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jicGlEPTB;MD6wNFA1ODdizszN MoPMV2FPT0WU
NCI-SNU-1 M1jrNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\pPGlEPTB;MD6wNFIxPyEQvF2= NEDaNFlUSU6JRWK=
FADU MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITveWNKSzVyPUCuNFAzODlizszN NYPWSo9SW0GQR1XS
C32 NFHhZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMECzNFQh|ryP NVPmeYdzW0GQR1XS
D-566MG M1u0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zoNWlEPTB;MD6wNFM6KM7:TR?= MXHTRW5ITVJ?
LXF-289 MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu5bIdKSzVyPUCuNFA1OTlizszN MmOxV2FPT0WU
HGC-27 NWXkWXZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTuTWM2OD1yLkCwOVEh|ryP NIjk[mNUSU6JRWK=
RPMI-7951 NGf0Um1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMEC3NVch|ryP MXzTRW5ITVJ?
HSC-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnkTWM2OD1yLkCwPVI6KM7:TR?= M{m4fnNCVkeHUh?=
MIA-PaCa-2 NWXTXGNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMEGwNFkh|ryP M1GwdXNCVkeHUh?=
KS-1 M{C0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rVOmlEPTB;MD6wNVM2PSEQvF2= NF30VWlUSU6JRWK=
CAL-51 M4LEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMEG0NFUh|ryP NF\CcIxUSU6JRWK=
MDA-MB-361 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMEG0PVUh|ryP Mn6zV2FPT0WU
TI-73 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHyfoNCUUN3ME2wMlAyPzl4IN88US=> MkDqV2FPT0WU
AGS NUHzZVB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HkR2lEPTB;MD6wNVk{QCEQvF2= MXTTRW5ITVJ?
NCI-H460 NXLXZXNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXETWM2OD1yLkCxPVc1KM7:TR?= MnvNV2FPT0WU
A204 NGLI[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q5OWlEPTB;MD6wNlI1QSEQvF2= MkixV2FPT0WU
CHL-1 NXjtZWQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrnO21KSzVyPUCuNFIzPTFizszN NGLLZlVUSU6JRWK=
DU-4475 NUntOHg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;aNJA1UUN3ME2wMlAzOjZzIN88US=> MYPTRW5ITVJ?
CGTH-W-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe3W2ZKSzVyPUCuNFI{PDlizszN NIPudZRUSU6JRWK=
HCC2218 NG[xdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEK0PVQh|ryP MWDTRW5ITVJ?
A2780 NXzPb4tiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33l[GlEPTB;MD6wNlU{OSEQvF2= NHnNfHhUSU6JRWK=
NCI-H720 NYrxToh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrzSWQzUUN3ME2wMlAzPTR4IN88US=> NXHJ[29xW0GQR1XS
NCI-N87 NFjtRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjBTWM2OD1yLkCyOVk{KM7:TR?= MXjTRW5ITVJ?
CHP-212 NHraNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\ocWNKSzVyPUCuNFI3OjhizszN NW\hZ2trW0GQR1XS
NCI-H23 NFzPSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMEK2OlUh|ryP MlTDV2FPT0WU
D-263MG MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfVOZlKSzVyPUCuNFI4QDZizszN NYX0[GxCW0GQR1XS
ME-180 NXzyUXc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe3cVBKSzVyPUCuNFI5QTFizszN NFvVVHVUSU6JRWK=
SW982 M3HYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTWTWM2OD1yLkCyPVk6KM7:TR?= MU\TRW5ITVJ?
OE19 NY\0ZlVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnTTWM2OD1yLkCzNFc4KM7:TR?= Mom2V2FPT0WU
SK-LU-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMEOwPFIh|ryP M{K4TnNCVkeHUh?=
H4 NFrDOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvLTWM2OD1yLkCzNFkh|ryP MmHSV2FPT0WU
HT-144 M37BWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DTS2lEPTB;MD6wN|A6OyEQvF2= Mn3vV2FPT0WU
SK-UT-1 M{D6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4GwWmlEPTB;MD6wN|E4QCEQvF2= NYLH[JVHW0GQR1XS
D-336MG MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMEOzNFkh|ryP Ml7yV2FPT0WU
MDA-MB-175-VII MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fDXWlEPTB;MD6wN|M2PCEQvF2= MnP0V2FPT0WU
GAMG MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMEO0N|Uh|ryP NWjvdXJ2W0GQR1XS
CP50-MEL-B MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfscZBKSzVyPUCuNFM1PSEQvF2= M{[y[HNCVkeHUh?=
OVCAR-5 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnoSlBUUUN3ME2wMlA{PDhizszN NIjtc4FUSU6JRWK=
SK-MES-1 NHTqRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofVTWM2OD1yLkCzOlA3KM7:TR?= NXTNXoJoW0GQR1XS
VM-CUB-1 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPL[FhKSzVyPUCuNFM3PTdizszN NYTybHQxW0GQR1XS
WM-115 NEnkSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojNTWM2OD1yLkCzO|YzKM7:TR?= MWXTRW5ITVJ?
DSH1 NGrV[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7BbINDUUN3ME2wMlA{QDB5IN88US=> NYnzSZg5W0GQR1XS
Becker M3\Hfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMEO4PFUh|ryP NEPBR3JUSU6JRWK=
SW962 Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP3TWM2OD1yLkCzPVQ2KM7:TR?= M12yZ3NCVkeHUh?=
TYK-nu MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\EZlZKSzVyPUCuNFM6QDVizszN MnT1V2FPT0WU
HO-1-N-1 NH\FcINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DKeGlEPTB;MD6wOFAzOSEQvF2= MVTTRW5ITVJ?
T98G NGTzemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMESxNFMh|ryP NVr6VopwW0GQR1XS
ACN M4nsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV24TFkyUUN3ME2wMlA1OTZ{IN88US=> MlfKV2FPT0WU
SW780 NXLmXZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DxUmlEPTB;MD6wOFIxOyEQvF2= MUnTRW5ITVJ?
Detroit562 NHfvVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMESyN|kh|ryP M4HHUnNCVkeHUh?=
BB49-HNC M1HTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi1TWM2OD1yLkC0NlQ{KM7:TR?= NX31dpBXW0GQR1XS
HN M2Hmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXMbGNTUUN3ME2wMlA1Ojd{IN88US=> MkDqV2FPT0WU
H9 MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfhZVliUUN3ME2wMlA1OzdzIN88US=> MWfTRW5ITVJ?
VA-ES-BJ Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDsemJIUUN3ME2wMlA1PDR5IN88US=> NETLVIZUSU6JRWK=
MEL-JUSO NF3mT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXybFdKSzVyPUCuNFQ1PzVizszN M2\zTHNCVkeHUh?=
BT-474 M3zCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrDdpBKSzVyPUCuNFQ2KM7:TR?= M{jLc3NCVkeHUh?=
CaR-1 NHX6XFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGOxWnVKSzVyPUCuNFQ2PDlizszN MWLTRW5ITVJ?
PSN1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzN[|BQUUN3ME2wMlA1PjB|IN88US=> NW[2UpFJW0GQR1XS
KYSE-510 NGjPS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTkVZBKSzVyPUCuNFQ3PDlizszN NWDiO2F{W0GQR1XS
KP-4 NV;TNIVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nKXWlEPTB;MD6wOFc2OyEQvF2= Mmi5V2FPT0WU
KYSE-410 NHHDc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr1TWM2OD1yLkC0O|czKM7:TR?= M4XsdHNCVkeHUh?=
G-402 Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7jdFZKSzVyPUCuNFQ4QDlizszN NFjabWlUSU6JRWK=
DOK NY\RO29{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMES5NFIh|ryP M2C1R3NCVkeHUh?=
COR-L88 NUTXU|MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7xTWM2OD1yLkC0PVEzKM7:TR?= NVi2Z21jW0GQR1XS
SKG-IIIa MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\STWM2OD1yLkC0PVg3KM7:TR?= NIH4eFFUSU6JRWK=
AN3-CA NVPIO5ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMEWg{txO MmL1V2FPT0WU
SW48 NEPUXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHzc21lUUN3ME2wMlA2ODN7IN88US=> MmHXV2FPT0WU
YKG-1 MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMEWwO|Eh|ryP MlrOV2FPT0WU
KYSE-150 NHrz[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:3TWM2OD1yLkC1NlM2KM7:TR?= MUDTRW5ITVJ?
HuO-3N1 NXO4WIVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLCcG9KSzVyPUCuNFUzOzdizszN NF33[2JUSU6JRWK=
LB1047-RCC NUXuUmtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMEWyPVYh|ryP MX3TRW5ITVJ?
NCI-H2030 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMEW0NVQh|ryP Ml3JV2FPT0WU
YH-13 NEewXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEW3NlIh|ryP NV7CRXNLW0GQR1XS
5637 M1\D[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL5TWM2OD1yLkC1O|Qh|ryP NFqxR4FUSU6JRWK=
LOXIMVI M2[zWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLpTWM2OD1yLkC1PFczKM7:TR?= NF3HSJdUSU6JRWK=
GT3TKB NGHUTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMEW5OFIh|ryP MXfTRW5ITVJ?
TCCSUP M{PrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn1UGtDUUN3ME2wMlA2QTZ2IN88US=> NF7KV3VUSU6JRWK=
EPLC-272H NIHlPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi3dWtKSzVyPUCuNFYzODVizszN MYXTRW5ITVJ?
LU-99A M1noNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwME[yN|ch|ryP MnHhV2FPT0WU
NCI-H1755 M320VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\sTWM2OD1yLkC2N|QyKM7:TR?= M3vLXXNCVkeHUh?=
KM12 MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwME[zOFgh|ryP M2ix[nNCVkeHUh?=
SF295 MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlmzTWM2OD1yLkC2OFUzKM7:TR?= NWTz[ZNxW0GQR1XS
MZ2-MEL MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXuV5FKSzVyPUCuNFY2PTNizszN NFrMclBUSU6JRWK=
HEC-1 MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv0TWM2OD1yLkC2OVg5KM7:TR?= MmruV2FPT0WU
SW684 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV62fnlLUUN3ME2wMlA3PTlzIN88US=> M3PVNHNCVkeHUh?=
SF539 M3TCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\wTWM2OD1yLkC2OlgyKM7:TR?= MWXTRW5ITVJ?
GMS-10 NV65S3hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7PTWM2OD1yLkC2Olk6KM7:TR?= NHPtbmVUSU6JRWK=
MV-4-11 NGryfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLBSYFQUUN3ME2wMlA3QDB|IN88US=> NYfxOZR5W0GQR1XS
HT-29 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTiUoJKSzVyPUCuNFY6OTlizszN M2DzTXNCVkeHUh?=
23132-87 M3nQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzkfG1LUUN3ME2wMlA3QTVizszN NX24[3pIW0GQR1XS
SW620 NY\oV4FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXOeo1KSzVyPUCuNFcxOjZizszN NXWy[lFqW0GQR1XS
HCC1806 Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq1TWM2OD1yLkC3NVMyKM7:TR?= NI\mSJRUSU6JRWK=
Hs-578-T Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDXTWM2OD1yLkC3NlA5KM7:TR?= NGDiTYRUSU6JRWK=
A2058 Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XXSGlEPTB;MD6wO|IzQCEQvF2= NHviOoVUSU6JRWK=
MEL-HO M1zrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7EbYtKSzVyPUCuNFczPTVizszN M{n2S3NCVkeHUh?=
HCC2998 MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjHRmhKSzVyPUCuNFc{PDdizszN NU\0T412W0GQR1XS
HuO9 MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEP5W|BKSzVyPUCuNFc2QDlizszN NX7XR3NTW0GQR1XS
CAL-39 NYTzPI51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rtWmlEPTB;MD6wO|c3PiEQvF2= M3\5TXNCVkeHUh?=
M14 M3vPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLLNGZKSzVyPUCuNFc6OTNizszN NIHh[2ZUSU6JRWK=
BFTC-909 NYC2XVJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HTTWlEPTB;MD6wO|k3QSEQvF2= MVPTRW5ITVJ?
TE-11 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS4W3hlUUN3ME2wMlA4QTl4IN88US=> MnfzV2FPT0WU
TGBC1TKB NVSwbGF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fNbGlEPTB;MD6wPFA1OyEQvF2= NEiyZZlUSU6JRWK=
L-363 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzsUWVKSzVyPUCuNFgzODZizszN NXu5U5B6W0GQR1XS
A431 M4jU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LsWGlEPTB;MD6wPFIyKM7:TR?= MVjTRW5ITVJ?
MKN45 MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLxWVdKSzVyPUCuNFgzOTlizszN MUHTRW5ITVJ?
HT-1080 NG\oVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\1TWM2OD1yLkC4OFM6KM7:TR?= M{HR[XNCVkeHUh?=
OVCAR-8 M3PVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEi2NlIh|ryP MnT2V2FPT0WU
LCLC-97TM1 NGDIcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvNVYhZUUN3ME2wMlA5PzJ6IN88US=> NX3oS4JIW0GQR1XS
M059J NF\yRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMEmwNlch|ryP MX3TRW5ITVJ?
SK-MEL-2 NIrUWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zPVmlEPTB;MD6wPVA3KM7:TR?= M37GeXNCVkeHUh?=
TE-1 NEHmTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfzTWM2OD1yLkC5NlA1KM7:TR?= M2PhSHNCVkeHUh?=
KYSE-180 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMEmyOlIh|ryP MofLV2FPT0WU
D-247MG M4HrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMEm0OVUh|ryP NYfHcVFxW0GQR1XS
8-MG-BA MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD2R4pqUUN3ME2wMlA6PDd{IN88US=> NGG0RmFUSU6JRWK=
NCI-H1792 NUTWbllCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmzTWM2OD1yLkC5OlE5KM7:TR?= Mk[yV2FPT0WU
MCF7 Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\0[5JKSzVyPUCuNFk3PzdizszN NWPjPJpoW0GQR1XS
NCI-H2122 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfkTWM2OD1yLkC5O|Q2KM7:TR?= MmHWV2FPT0WU
EFO-27 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMEm5PVch|ryP Mn76V2FPT0WU
LB2241-RCC NICyTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInYeZJKSzVyPUCuNVAxPTRizszN NYPLZmw4W0GQR1XS
SN12C NH7WO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv4TWM2OD1yLkGwNVA4KM7:TR?= MW\TRW5ITVJ?
A498 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT0SmJiUUN3ME2wMlExOThizszN MW\TRW5ITVJ?
PANC-03-27 NEjoZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTqTWM2OD1yLkGwNlg3KM7:TR?= MXzTRW5ITVJ?
NCI-H1581 MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rQc2lEPTB;MD6xNFI6KM7:TR?= Ml:5V2FPT0WU
U-87-MG M2\ObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMUCzNFch|ryP MnvvV2FPT0WU
G-401 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX20TJZuUUN3ME2wMlExOzV|IN88US=> NGD5RpNUSU6JRWK=
SiHa NVfwOoV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMUC0PFYh|ryP MWHTRW5ITVJ?
U251 NWjWOmlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7VTWM2OD1yLkGwOVI2KM7:TR?= NFTTcmZUSU6JRWK=
MMAC-SF MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHkcXZlUUN3ME2wMlExPTNzIN88US=> NFP4SHJUSU6JRWK=
BB65-RCC NWnI[pFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y5O2lEPTB;MD6xNFU2PCEQvF2= NIHlPXlUSU6JRWK=
NKM-1 M3XmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uzPGlEPTB;MD6xNFY3PiEQvF2= MlniV2FPT0WU
HD-MY-Z NUfWdG5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMUC4O|Mh|ryP MnW5V2FPT0WU
TGBC11TKB M3XwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r6[GlEPTB;MD6xNFkxOyEQvF2= NITQSoZUSU6JRWK=
COLO-679 M2\jXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli1TWM2OD1yLkGxNlEyKM7:TR?= NVnTcZlzW0GQR1XS
TE-8 M17VSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHwR4x{UUN3ME2wMlEyOjZ2IN88US=> M{XTR3NCVkeHUh?=
SK-MEL-28 NY\j[nVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzhTXdKSzVyPUCuNVE{OjFizszN NFr1NVhUSU6JRWK=
SH-4 NXHTUIR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M121eGlEPTB;MD6xNVM2PiEQvF2= NID4dG9USU6JRWK=
KALS-1 NX;C[HR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzpO|BwUUN3ME2wMlEyOzl|IN88US=> MX7TRW5ITVJ?
RKO NWT6SXJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTrVGIyUUN3ME2wMlEyPzZ2IN88US=> M3HLSXNCVkeHUh?=
OMC-1 NEPSeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfoTWM2OD1yLkGxO|k4KM7:TR?= NVfEb2lqW0GQR1XS
BT-549 MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r0cmlEPTB;MD6xNVc6QSEQvF2= MWnTRW5ITVJ?
NCI-H28 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HVTGlEPTB;MD6xNVgyPyEQvF2= MnXwV2FPT0WU
RXF393 MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\rUHJjUUN3ME2wMlEyQTh{IN88US=> NEjsbHZUSU6JRWK=
COLO-829 NGi4OplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXzbIhKSzVyPUCuNVIxODVizszN NH3ZUo9USU6JRWK=
HMV-II NHrvRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DlfmlEPTB;MD6xNlAzKM7:TR?= M1jhRnNCVkeHUh?=
SW1990 NIDBNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW0U41IUUN3ME2wMlEzOTV5IN88US=> NID3S2JUSU6JRWK=
NCI-H1437 M3TrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;6TJFKSzVyPUCuNVIyPTdizszN MXjTRW5ITVJ?
SNB75 Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL5TWM2OD1yLkGyNVY6KM7:TR?= M2XxVXNCVkeHUh?=
EW-3 M4PZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfBWFdxUUN3ME2wMlEzPjZzIN88US=> MlO3V2FPT0WU
SAS MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTCdZNKSzVyPUCuNVI3QSEQvF2= NFq5UGZUSU6JRWK=
NCI-H1666 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjLTWM2OD1yLkGyO|c1KM7:TR?= NXLm[FVSW0GQR1XS
A375 Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMUK3O|gh|ryP NEjFZmZUSU6JRWK=
CAMA-1 NF7ucWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfXTWM2OD1yLkGyPVI1KM7:TR?= NWOyfXRPW0GQR1XS
HuP-T4 Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLxTWM2OD1yLkGyPVQ{KM7:TR?= NV7GTlR[W0GQR1XS
NCI-H292 MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fPNGlEPTB;MD6xN|EyKM7:TR?= MYTTRW5ITVJ?
PC-14 NWXIc|BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDQc2ZKSzVyPUCuNVMzOTFizszN MX7TRW5ITVJ?
BPH-1 M3r1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S5NGlEPTB;MD6xN|QyKM7:TR?= MkXQV2FPT0WU
GAK MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLYTWM2OD1yLkGzOVY4KM7:TR?= NYDlZotwW0GQR1XS
VMRC-RCZ MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPtTWM2OD1yLkGzO|YzKM7:TR?= NH74NIJUSU6JRWK=
SK-MEL-24 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMUO4O{DPxE1? NYPveZJjW0GQR1XS
LB831-BLC M2fMeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7STZlKSzVyPUCuNVM5QDNizszN MYjTRW5ITVJ?
NCI-H2452 NUDnb3ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPYXHdKSzVyPUCuNVM6PTZizszN MnPPV2FPT0WU
RT-112 NHruNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7UTWM2OD1yLkG0NFM2KM7:TR?= M4HUcHNCVkeHUh?=
GP5d MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PrSWlEPTB;MD6xOFExPCEQvF2= NFXGenRUSU6JRWK=
LC-2-ad M2G2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jRd2lEPTB;MD6xOFEzOSEQvF2= MVPTRW5ITVJ?
MPP-89 NUPUWYsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\2cXdKSzVyPUCuNVQyOjVizszN Mn3rV2FPT0WU
NUGC-3 NWDke3JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;hcmlEPTB;MD6xOFQ4QCEQvF2= NV\OdXhLW0GQR1XS
GI-1 Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnQW4hpUUN3ME2wMlE1PTV6IN88US=> MoHDV2FPT0WU
HCC1419 NHLOTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELPTlJKSzVyPUCuNVQ2PzZizszN MWDTRW5ITVJ?
SW1573 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH20R5pKSzVyPUCuNVQ4PThizszN NV7YfW1ZW0GQR1XS
NCI-H2347 NHXPXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDFTWRKSzVyPUCuNVQ5OzlizszN NX7aWWhlW0GQR1XS
Mewo NHfyeo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r4ZWlEPTB;MD6xOFg5QSEQvF2= NX;q[Wl5W0GQR1XS
639-V MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H6O2lEPTB;MD6xOVAyOyEQvF2= NGTBVXNUSU6JRWK=
AsPC-1 M1fxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMUWyNlUh|ryP MWLTRW5ITVJ?
NCI-H1648 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCwU|VKSzVyPUCuNVUzOzJizszN MlPBV2FPT0WU
786-0 MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMUWzPFEh|ryP MWrTRW5ITVJ?
ETK-1 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMUW5JO69VQ>? MlGxV2FPT0WU
BxPC-3 MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fuV2lEPTB;MD6xOVk3PiEQvF2= Moj5V2FPT0WU
CAL-62 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMU[xOlkh|ryP MXjTRW5ITVJ?
HCC1937 MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\BTWM2OD1yLkG2Nlc2KM7:TR?= MWHTRW5ITVJ?
NCI-H1299 M3;5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\vS2lIUUN3ME2wMlE3Ojh3IN88US=> NVHmNY5WW0GQR1XS
SW1088 Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnuXmxSUUN3ME2wMlE3PDF|IN88US=> NYezdGN[W0GQR1XS
FTC-133 NGX3W|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jzSGlEPTB;MD6xOlU1KM7:TR?= M4PuRXNCVkeHUh?=
OC-314 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17oPGlEPTB;MD6xOlY6KM7:TR?= MWDTRW5ITVJ?
SCC-9 M4ThfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMU[3NVYh|ryP NWPjTlA5W0GQR1XS
HT-1376 M{m2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMU[5N|Yh|ryP NHPCO3ZUSU6JRWK=
U-2-OS NIfVRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnRTWM2OD1yLkG3NVc{KM7:TR?= MlK5V2FPT0WU
COLO-824 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwMUeyPVQh|ryP NIm5SopUSU6JRWK=
BB30-HNC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMUezN{DPxE1? MoLYV2FPT0WU
NCI-H2087 NIXJfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjFT4ptUUN3ME2wMlE4OzZ6IN88US=> NVfRNJRvW0GQR1XS
NCI-H2170 M{TEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W3eGlEPTB;MD6xO|U{PiEQvF2= M1;JPHNCVkeHUh?=
SK-OV-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3XOVJKSzVyPUCuNVc2PzFizszN Mn\iV2FPT0WU
MZ7-mel MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS0N3hKSzVyPUCuNVc3PDlizszN NEjRdFFUSU6JRWK=
NCI-H650 NXzKPVVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jUSmlEPTB;MD6xO|Y5OiEQvF2= MYTTRW5ITVJ?
KOSC-2 M3vpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTtTWM2OD1yLkG3O|M1KM7:TR?= NW\5dZp6W0GQR1XS
SCC-4 NYrwWodUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nrO2lEPTB;MD6xO|c4PyEQvF2= NULKRlI2W0GQR1XS
MDA-MB-157 NWjSfmsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMUiwPFIh|ryP M3nOVnNCVkeHUh?=
KYSE-520 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLoTWM2OD1yLkG4NkDPxE1? M2S5fnNCVkeHUh?=
LK-2 NFnxemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMUizNFMh|ryP NXHtdVZyW0GQR1XS
KNS-81-FD NXnzPHdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS0O3l2UUN3ME2wMlE5Ozl2IN88US=> MXTTRW5ITVJ?
IGROV-1 NYn5blVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK0bnZqUUN3ME2wMlE5PDR|IN88US=> NXLlN4tsW0GQR1XS
DEL NYX5S41mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jERmlEPTB;MD6xPFQ2KM7:TR?= NUnOVIdKW0GQR1XS
NCI-H1395 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrTd3VKSzVyPUCuNVg3QDJizszN MnG3V2FPT0WU
JEG-3 MoK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[2Z|ltUUN3ME2wMlE5PzB3IN88US=> M4i2WnNCVkeHUh?=
BCPAP MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq1[o9KSzVyPUCuNVg5PzJizszN MmWyV2FPT0WU
CAL-27 MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMUmwNlIh|ryP M1;COXNCVkeHUh?=
RD NVPjUHZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLxTWM2OD1yLkG5NVE{KM7:TR?= NX[zVpJDW0GQR1XS
RVH-421 NGCycZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XKOGlEPTB;MD6xPVEyPiEQvF2= M4f0ZXNCVkeHUh?=
Capan-2 NGmzfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv1TWM2OD1yLkG5NlU3KM7:TR?= M1PQT3NCVkeHUh?=
COLO-680N M3e4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMUmzOlQh|ryP MnTZV2FPT0WU
NCI-H1650 NHfh[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP5epR[UUN3ME2wMlIxODV5IN88US=> NHnIfIVUSU6JRWK=
SBC-5 M3LxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j4dGlEPTB;MD6yNFEyQCEQvF2= MWjTRW5ITVJ?
U031 NFHZNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPrUGxKSzVyPUCuNlA2PDdizszN NEO3dopUSU6JRWK=
S-117 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7RTWM2OD1yLkKwOVY1KM7:TR?= NUPiO3lYW0GQR1XS
DoTc2-4510 NF;PW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\ScnFKSzVyPUCuNlA4PjlizszN MmTsV2FPT0WU
AM-38 M{ftdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXYTWM2OD1yLkKwPFQ5KM7:TR?= NULsWmdIW0GQR1XS
A172 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPuTG51UUN3ME2wMlIyODJ{IN88US=> M{DsU3NCVkeHUh?=
HPAF-II M3H4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLmdVNLUUN3ME2wMlIyOjZ2IN88US=> M373dXNCVkeHUh?=
769-P MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMkGyPEDPxE1? MXfTRW5ITVJ?
MFE-280 NGX2[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLtTWM2OD1yLkKxNlk5KM7:TR?= NXnnenZkW0GQR1XS
TE-9 NGnDblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTITWM2OD1yLkKxO|g3KM7:TR?= MoDCV2FPT0WU
C2BBe1 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO4eYZKSzVyPUCuNlIyQSEQvF2= MU\TRW5ITVJ?
EoL-1-cell M1PWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;QXplXUUN3ME2wMlIzOjB|IN88US=> NYL4S5luW0GQR1XS
G-361 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPpTWM2OD1yLkKyOlgzKM7:TR?= MnXPV2FPT0WU
KYSE-270 NF7ofnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMkOwPFQh|ryP M{LrXnNCVkeHUh?=
TK10 MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGiwVIJKSzVyPUCuNlMyOTdizszN Ml;rV2FPT0WU
ML-2 M4HIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXTbmpDUUN3ME2wMlI{OTF7IN88US=> NFL6O3hUSU6JRWK=
MHH-ES-1 NWDLN2syT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMkO2PFEh|ryP MlT0V2FPT0WU
BHY NFzIdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzNTFR3UUN3ME2wMlI{PjlzIN88US=> NELxTWtUSU6JRWK=
LS-513 NX:0UXV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrWXVNKSzVyPUCuNlM6PjFizszN M1\pVXNCVkeHUh?=
COLO-678 NUjUSW1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfCblN4UUN3ME2wMlI1ODR2IN88US=> NFzyWYRUSU6JRWK=
NCI-H747 NV\BZlgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLBc5g1UUN3ME2wMlI1OTZ7IN88US=> MoTxV2FPT0WU
K5 NEjjNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnLS|l6UUN3ME2wMlI1OzhizszN MVfTRW5ITVJ?
OS-RC-2 NWjaVmNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq2TWM2OD1yLkK0OVA6KM7:TR?= NVPTeYpoW0GQR1XS
KINGS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMkS1Nlkh|ryP MnrEV2FPT0WU
SCC-25 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\MSpFKSzVyPUCuNlQ2PjNizszN NYrkbIRvW0GQR1XS
CAPAN-1 NHe1NolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT2VopKSzVyPUCuNlQ4QDNizszN MXrTRW5ITVJ?
ESS-1 MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomyTWM2OD1yLkK0PFA2KM7:TR?= M2TrR3NCVkeHUh?=
TE-6 NWnHVIZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jiUGlEPTB;MD6yOVc2KM7:TR?= NYLCWVlIW0GQR1XS
LB2518-MEL NUGwO245T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHWTWM2OD1yLkK1O|c4KM7:TR?= M33OUXNCVkeHUh?=
COLO-800 M2q2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLpTWM2OD1yLkK1PFEzKM7:TR?= NUn2bpZIW0GQR1XS
LU-134-A NVfxd4VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\SSmlEPTB;MD6yOlE{PiEQvF2= NIXXd3NUSU6JRWK=
NCI-H1155 NUjFeHQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMk[xOlIh|ryP NVPyPJpiW0GQR1XS
MFM-223 NHHwfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zycGlEPTB;MD6yOlM3OyEQvF2= MkTZV2FPT0WU
HTC-C3 NGjvdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzoTWM2OD1yLkK2OVA3KM7:TR?= MUfTRW5ITVJ?
HCT-116 NIjzcYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMk[1PVkh|ryP MWnTRW5ITVJ?
Ca-Ski MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHriZ|lKSzVyPUCuNlY3PzhizszN MWXTRW5ITVJ?
SBC-1 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPj[3BKSzVyPUCuNlY4PDJizszN NWezVIlmW0GQR1XS
NB69 NHvaeVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojlTWM2OD1yLkK3NFg4KM7:TR?= NUTxOldiW0GQR1XS
J82 NGjzNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMkeyOlUh|ryP M4f1XXNCVkeHUh?=
U-118-MG NGPxWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMke1O|kh|ryP NH7CTmZUSU6JRWK=
NCI-H1355 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH6emNnUUN3ME2wMlI5ODd2IN88US=> NITWb25USU6JRWK=
NCI-H1048 NYm2VpluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMki5OVYh|ryP MmmyV2FPT0WU
SW954 NV7CXlBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkewTWM2OD1yLkK5NlI4KM7:TR?= M4m1XHNCVkeHUh?=
NMC-G1 NIrQVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\oTWM2OD1yLkK5Nlc4KM7:TR?= MYfTRW5ITVJ?
SW1710 NIX1enpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMkm0PVQh|ryP MlS1V2FPT0WU
KY821 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMkm4O|Ih|ryP MkfxV2FPT0WU
HCC38 NFi4O29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvpPZdsUUN3ME2wMlMxODd6IN88US=> M4HaeHNCVkeHUh?=
NCI-SNU-5 M3K1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDOT|JKSzVyPUCuN|A2PCEQvF2= NX:2[Ho3W0GQR1XS
ES8 NIW5UXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwM{C3PFQh|ryP NFvVPFlUSU6JRWK=
COLO-792 NYfofm9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnvWY41UUN3ME2wMlMyOjVzIN88US=> NV7xR4hJW0GQR1XS
BFTC-905 NILBSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD1TWM2OD1yLkOxOVIyKM7:TR?= NFXlfo1USU6JRWK=
ChaGo-K-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwM{G3NVUh|ryP M1vzV3NCVkeHUh?=
Daoy M4roXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjpWHVKSzVyPUCuN|E4OjNizszN M4TrbHNCVkeHUh?=
SJSA-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTuTWM2OD1yLkOxPFQ4KM7:TR?= NHr5XXVUSU6JRWK=
KNS-62 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnrTWM2OD1yLkOyNFg5KM7:TR?= MmDHV2FPT0WU
CAKI-1 NGLnTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3VTWM2OD1yLkOyNVEyKM7:TR?= M2PWU3NCVkeHUh?=
UACC-62 Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG3WoZSUUN3ME2wMlMzOjJ5IN88US=> MnTCV2FPT0WU
HuCCT1 MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzJWGJKSzVyPUCuN|IzQDNizszN MkDqV2FPT0WU
CTB-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjxUWNDUUN3ME2wMlMzPzV|IN88US=> M1X6RnNCVkeHUh?=
NTERA-S-cl-D1 M2\1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwM{K4N|Yh|ryP MU\TRW5ITVJ?
T-24 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT4TWM2OD1yLkOzNVU6KM7:TR?= MnOxV2FPT0WU
KYSE-70 M3HPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIqwNnpKSzVyPUCuN|MzQDNizszN MYTTRW5ITVJ?
SW626 NH\pRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjzWZE4UUN3ME2wMlM{PTN{IN88US=> MlTvV2FPT0WU
LB996-RCC NVXaOZR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwM{O2NVkh|ryP NGfRVGxUSU6JRWK=
DMS-273 M2PYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnXSWhsUUN3ME2wMlM{QTF4IN88US=> NHrGSnBUSU6JRWK=
SW1783 M1nBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\uRWlEPTB;MD6zN|k6PyEQvF2= NFjTbHJUSU6JRWK=
KU812 M13Rcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlToTWM2OD1yLkO0NFM5KM7:TR?= NED4N45USU6JRWK=
HSC-2 M3XHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPpPXE2UUN3ME2wMlM1ODV|IN88US=> NFv6VohUSU6JRWK=
A3-KAW M{fScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTVd5lkUUN3ME2wMlM1OTZ{IN88US=> MWTTRW5ITVJ?
COLO-684 M1\3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17OZWlEPTB;MD6zOFUxOSEQvF2= Mnf2V2FPT0WU
NCI-H2405 MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LWUWlEPTB;MD6zOFY{OSEQvF2= Mn7yV2FPT0WU
NCI-H2228 NIK4NodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnzNpRKSzVyPUCuN|U{PTdizszN MVzTRW5ITVJ?
NB13 M2\0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwM{[4Nlkh|ryP MWLTRW5ITVJ?
no-11 MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW3dpBbUUN3ME2wMlM3QTVizszN M2jzfHNCVkeHUh?=
DK-MG NFK5fWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGOzNFRKSzVyPUCuN|cyQDhizszN NHrJXHJUSU6JRWK=
NBsusSR MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwM{eyPFUh|ryP Mn3TV2FPT0WU
KP-N-YS MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13JcWlEPTB;MD6zO|Q3OyEQvF2= M3zHRXNCVkeHUh?=
CFPAC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF65bXlKSzVyPUCuN|c2OThizszN M1LGNnNCVkeHUh?=
KARPAS-45 NVK4U2luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnZTWM2OD1yLkO3PFYzKM7:TR?= MnLnV2FPT0WU
NCI-H1793 M{TnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13FdWlEPTB;MD6zPFUyKM7:TR?= MlzYV2FPT0WU
HCE-T Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\uN4dxUUN3ME2wMlM5PjB|IN88US=> M4HVUHNCVkeHUh?=
NCI-H520 NID4VnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUGzVoNPUUN3ME2wMlM5PzB|IN88US=> MVHTRW5ITVJ?
HCC2157 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK4UpZDUUN3ME2wMlM5PzhzIN88US=> MUPTRW5ITVJ?
EW-18 M1HzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fiUGlEPTB;MD6zPFk1OSEQvF2= M4XMeXNCVkeHUh?=
RO82-W-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fhfmlEPTB;MD6zPVY6QSEQvF2= NUPBb2dDW0GQR1XS
HuP-T3 M4DqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwNECxOFMh|ryP M2DQd3NCVkeHUh?=
PANC-10-05 NIfZ[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFeyXI9KSzVyPUCuOFEyPyEQvF2= MoTOV2FPT0WU
NCI-H1703 NVv4d4l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwNEG0OFYh|ryP MoLiV2FPT0WU
TE-10 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwNEG0OFch|ryP NUDzXoNIW0GQR1XS
HOS NHLab3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nM[mlEPTB;MD60NVY5OiEQvF2= MX3TRW5ITVJ?
LN-405 NYXGfVloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwNEG2PFch|ryP M2fMOXNCVkeHUh?=
A427 M4nqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrYTWM2OD1yLkSxPVgyKM7:TR?= Mo\0V2FPT0WU
CAL-12T NEWySXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnpXYpKSzVyPUCuOFI4QCEQvF2= M3PBXXNCVkeHUh?=
SW756 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXFVnJKSzVyPUCuOFQyQDNizszN MkS2V2FPT0WU
YAPC M37CO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7xW2ZKSzVyPUCuOFUxQCEQvF2= M3X2NHNCVkeHUh?=
GOTO NXzKSW1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTkTWM2OD1yLkS1NVYh|ryP MnHKV2FPT0WU
C3A MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLIZYdKSzVyPUCuOFU1OzdizszN NFHTWHVUSU6JRWK=
UM-UC-3 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwNEW0O{DPxE1? NUC3NFFoW0GQR1XS
NCI-H1573 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nGO2lEPTB;MD60OVU3QSEQvF2= MWHTRW5ITVJ?
LS-411N NET3O|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvZcXNKSzVyPUCuOFY2OjdizszN NUj5[lV5W0GQR1XS
COR-L23 Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rhSmlEPTB;MD60Olc3PCEQvF2= Mn:3V2FPT0WU
HCE-4 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnGfYdYUUN3ME2wMlQ4PDR4IN88US=> M{TsPHNCVkeHUh?=
NCI-H2291 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP2TWM2OD1yLkS3PFk3KM7:TR?= NEXjSpdUSU6JRWK=
A101D MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnWwTWM2OD1yLkS4NFU{KM7:TR?= MlzQV2FPT0WU
HT-3 NHP4doVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTEZ3NKSzVyPUCuOFgzOTdizszN NX3pbXNUW0GQR1XS
HOP-62 M4iyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPPVm5KSzVyPUCuOFk5PjVizszN MV7TRW5ITVJ?
PC-3 NWOzOIc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjPW5hKSzVyPUCuOVE2ODdizszN MnzrV2FPT0WU
CTV-1 NGjMfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjxTWM2OD1yLkWyOlY6KM7:TR?= M3frfHNCVkeHUh?=
PANC-08-13 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HFO2lEPTB;MD61N|E4PyEQvF2= M4LhVHNCVkeHUh?=
CAL-120 NV61cGJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWexbohxUUN3ME2wMlU{Ozl7IN88US=> MVnTRW5ITVJ?
UMC-11 Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlraTWM2OD1yLkW1NlM1KM7:TR?= MWDTRW5ITVJ?
MSTO-211H MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTMTWM2OD1yLkW1O|YzKM7:TR?= MU\TRW5ITVJ?
NCI-H2126 NULaWVNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjYV|ZKSzVyPUCuOVY5OTVizszN Mn3hV2FPT0WU
SNU-C2B MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37vN2lEPTB;MD61O|k4PyEQvF2= MmLDV2FPT0WU
DBTRG-05MG NWTjSpM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrvTWM2OD1yLkW4NFU{KM7:TR?= NHvHZ3JUSU6JRWK=
MKN1 NWLzWpVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwNUi3PFMh|ryP M17pSHNCVkeHUh?=
ES3 NYr6N4h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwNUmxNlQh|ryP MlnzV2FPT0WU
OVCAR-3 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nxXmlEPTB;MD61PVM1OSEQvF2= MUHTRW5ITVJ?
ACHN MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D4[2lEPTB;MD62NFU3QSEQvF2= Ml7sV2FPT0WU
SW872 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvhdYZzUUN3ME2wMlYxPzZ|IN88US=> NH;EOI9USU6JRWK=
CP66-MEL NUm1PIdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHRbWJKSzVyPUCuOlA6PjlizszN MnzXV2FPT0WU
NCI-H661 NHPoNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDVTWM2OD1yLk[xNVA1KM7:TR?= M4ruUnNCVkeHUh?=
UACC-893 NV3MUINRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L4S2lEPTB;MD62N|Y5OSEQvF2= NGXHeVBUSU6JRWK=
JVM-3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PNS2lEPTB;MD62N|gxPCEQvF2= MmfkV2FPT0WU
SF268 NWDmdVNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwNkSzOFkh|ryP NF7k[Y9USU6JRWK=
OCI-AML2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwNkWzPVch|ryP NX\mZpl2W0GQR1XS
RPMI-8226 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwNk[zNlMh|ryP NYLDfFFMW0GQR1XS
MKN28 NHjHc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwNk[2NlQh|ryP NVzQfZFPW0GQR1XS
MDA-MB-453 M{fCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnznTWM2OD1yLk[3NVgh|ryP MUHTRW5ITVJ?
BV-173 MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T6XmlEPTB;MD62PFY4QSEQvF2= MYTTRW5ITVJ?
NCI-H358 NIjTe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zxeWlEPTB;MD62PFczPiEQvF2= M2fvSXNCVkeHUh?=
NCI-H1651 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W3UWlEPTB;MD63JO69VQ>? NWW1Z3RQW0GQR1XS
MDA-MB-415 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:zTWM2OD1yLkewPFI6KM7:TR?= NWjkbJlpW0GQR1XS
8305C M3vKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHZT5V4UUN3ME2wMlczPDl6IN88US=> NEDG[FFUSU6JRWK=
EFM-19 M3;Q[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX6TWM2OD1yLkezOlcyKM7:TR?= NUezXYpZW0GQR1XS
RERF-LC-MS NYTHVW5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jUZ2lEPTB;MD63OFYyOyEQvF2= MnnUV2FPT0WU
A388 NXzlOI5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEm1cXdKSzVyPUCuO|Y1PjdizszN NHjudIhUSU6JRWK=
GI-ME-N M1LOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnaTWM2OD1yLke3NlM2KM7:TR?= NHz0OmJUSU6JRWK=
IGR-1 NILiZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwN{mwOFMh|ryP MmThV2FPT0WU
LNCaP-Clone-FGC NWfHU2tHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL4TWM2OD1yLkiwNFA1KM7:TR?= NGG2WYlUSU6JRWK=
SK-MEL-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrtb4VbUUN3ME2wMlgyPTB6IN88US=> NISyeJZUSU6JRWK=
UACC-257 NUnjbZRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfwSpNMUUN3ME2wMlgzOjNzIN88US=> MnHsV2FPT0WU
OE33 Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwOEWxNFEh|ryP M{nMOXNCVkeHUh?=
QIMR-WIL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjmdGZKSzVyPUCuPFUyPDFizszN M17WR3NCVkeHUh?=
NCI-H2009 NXjmUJJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHlfIlKSzVyPUCuPFU{OTFizszN MYXTRW5ITVJ?
NCI-H522 Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3ZUXVkUUN3ME2wMlg4Pzh|IN88US=> NHezWHNUSU6JRWK=
Saos-2 NVG3fldkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwOEe4O|Eh|ryP NUPaempkW0GQR1XS
NB17 NHm2WpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwOEiwNlUh|ryP Mk\5V2FPT0WU
D-392MG NWOwU3F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPuSZpvUUN3ME2wMlg6OzV4IN88US=> MULTRW5ITVJ?
SHP-77 M3rpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33MeWlEPTB;MD65NFQ5PSEQvF2= MXPTRW5ITVJ?
SK-MEL-30 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnXXVlKSzVyPUCuPVEyQDVizszN MX;TRW5ITVJ?
GCIY M3Prbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rRcWlEPTB;MD65NVg1OyEQvF2= M{TaZXNCVkeHUh?=
HCC70 NUH6XVN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojITWM2OD1yLkmyNFU6KM7:TR?= NIfqW3dUSU6JRWK=
LU-65 NF3vZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwOUK1PVEh|ryP NULS[YdQW0GQR1XS
NCI-H1563 NIHqO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTOTWM2OD1yLkm0PFY2KM7:TR?= MlPFV2FPT0WU
KURAMOCHI NX;VcVJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjmUHZKSzVyPUCuPVUyQTJizszN MnPWV2FPT0WU
PA-1 M3fhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWryN|g6UUN3ME2wMlk2PDJ2IN88US=> NVvNUZVrW0GQR1XS
NOS-1 M2\PdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwOUe0PFkh|ryP M3vVTnNCVkeHUh?=
NCI-H69 M2PuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXZTWM2OD1yLkm3OlM1KM7:TR?= MoDmV2FPT0WU
KYSE-450 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPNVYUxUUN3ME2wMlk5PjJ4IN88US=> MWrTRW5ITVJ?
8505C MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwOUm5PFIh|ryP MoDvV2FPT0WU
TGBC24TKB NHizOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\zd3VDUUN3ME2xMlAxODh2IN88US=> MojRV2FPT0WU
PFSK-1 NE[xZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\5fI91UUN3ME2xMlAyPDJ6IN88US=> MlzRV2FPT0WU
EKVX M2jEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVewcnROUUN3ME2xMlA{OTJzIN88US=> NETk[5RUSU6JRWK=
RCM-1 NH;ITlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFwMEW1NFch|ryP NES2c2dUSU6JRWK=
SW900 NIfwR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHLTWM2OD1zLkC3PFMh|ryP NI\3cXdUSU6JRWK=
D-542MG NXrJZYJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XUNWlEPTB;MT6wO|g2PSEQvF2= NUXRTFFGW0GQR1XS
SK-PN-DW M3TWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwMUCwOVYh|ryP MUPTRW5ITVJ?
NCI-H727 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzpTWM2OD1zLkGwNVU1KM7:TR?= M{G5d3NCVkeHUh?=
SW837 NXn5Z4VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvmXWpKSzVyPUGuNVA6PTRizszN NX:0UG5DW0GQR1XS
BT-20 NVe3bnZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF33[HJKSzVyPUGuNVEzODRizszN NUO1XY9XW0GQR1XS
RH-18 MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrmTWM2OD1zLkGzNVA{KM7:TR?= NI[2RXdUSU6JRWK=
TE-12 M4LscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T5XGlEPTB;MT6xN|M{OyEQvF2= MYXTRW5ITVJ?
NB10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTMe4VKSzVyPUGuNVM{PDRizszN NH\aflZUSU6JRWK=
AU565 NGPqZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrTTG9KSzVyPUGuNVU6PzNizszN NHK1bJZUSU6JRWK=
OAW-42 NEHWVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTRRYZKSzVyPUGuNVg{ODZizszN M1PGTnNCVkeHUh?=
DJM-1 NG\LRm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK2U|FKSzVyPUGuNVk5QDFizszN NX3GO3UxW0GQR1XS
HH MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn2TI9WUUN3ME2xMlI{QDNzIN88US=> NVHTbpdpW0GQR1XS
LAMA-84 NVHsclNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTNfnNKSzVyPUGuNlc{QTRizszN MWXTRW5ITVJ?
KNS-42 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDTZ2o{UUN3ME2xMlMxOjl4IN88US=> M2rFcHNCVkeHUh?=
NCI-H2052 NUK0NXZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXzTWM2OD1zLkOwOVA4KM7:TR?= M1TRTHNCVkeHUh?=
MLMA MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[zVmlEPTB;MT6zNlQxPyEQvF2= NU\KelNwW0GQR1XS
NB12 M1SxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFwM{W2N|Yh|ryP MUTTRW5ITVJ?
NCI-H1838 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr2T2FKSzVyPUGuN|Y{ODZizszN NHLleZdUSU6JRWK=
NCI-H526 M3LHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm3TWM2OD1zLkO3PFU{KM7:TR?= M2TUfnNCVkeHUh?=
LS-123 NVS4VVJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFwM{mwPVQh|ryP MlfYV2FPT0WU
HDLM-2 MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7UUWt6UUN3ME2xMlM6OjdzIN88US=> MmTCV2FPT0WU
MC-IXC NYLpW5c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwNEKzO|Eh|ryP MkfWV2FPT0WU
HCT-15 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTMdZdKSzVyPUGuOFMxPjhizszN NWPHZYdmW0GQR1XS
NCI-H596 NXXiSoxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i4NGlEPTB;MT60OVA3OSEQvF2= NGfsWJBUSU6JRWK=
ZR-75-30 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXVW4dKSzVyPUGuOFcxQDJizszN NIPybm5USU6JRWK=
A704 NHXZV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjuWZFZUUN3ME2xMlY3PTZ|IN88US=> MornV2FPT0WU
OVCAR-4 M{LuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFwNkm2NFch|ryP Ml\PV2FPT0WU
SW1417 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD6do5KSzVyPUGuO|I5PDlizszN NWjxdI9EW0GQR1XS
CAS-1 MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;HNWJKSzVyPUGuO|M6OzZizszN MWfTRW5ITVJ?
IST-SL1 M{nDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f4ZmlEPTB;MT63PVc2QSEQvF2= MnexV2FPT0WU
A253 NHLMbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTCTWM2OD1zLkiyNlM6KM7:TR?= NF3W[4xUSU6JRWK=
EW-16 NHnjbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M121OGlEPTB;MT64Nlg4PSEQvF2= MmftV2FPT0WU
SK-NEP-1 Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnVe2pxUUN3ME2xMlg3QTh6IN88US=> MV3TRW5ITVJ?
NCI-H226 NIjIcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDDN4hKSzVyPUGuPFk{PTlizszN NWTvRZNoW0GQR1XS
HOP-92 NHr2dpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHveHRKSzVyPUGuPVYxQTlizszN MWfTRW5ITVJ?
NCI-H441 NG[wV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP2doxpUUN3ME2yMlAzOzN5IN88US=> Mk\0V2FPT0WU
LU-139 NVvmOHJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDmTWM2OD1{LkCzNVE1KM7:TR?= MXnTRW5ITVJ?
SJRH30 M2PSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknXTWM2OD1{LkC0NlU{KM7:TR?= MWTTRW5ITVJ?
MG-63 NWfYTnlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\Hc2tKSzVyPUKuNVQyOTFizszN MlrEV2FPT0WU
NH-12 NUHaNHBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPuTWM2OD1{LkG1NFA3KM7:TR?= MYDTRW5ITVJ?
NB7 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnXNnVvUUN3ME2yMlE6Pjd|IN88US=> M3TTOnNCVkeHUh?=
LB771-HNC M2rjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3npS2lEPTB;Mj6yNFU6PSEQvF2= NUjJO2pZW0GQR1XS
HCC1569 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LQWGlEPTB;Mj6yOFU5OyEQvF2= MYDTRW5ITVJ?
D-283MED M4\heWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXYZ2xjUUN3ME2yMlI1Pzh{IN88US=> NFXnUYxUSU6JRWK=
J-RT3-T3-5 NHLkTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnsTWM2OD1{LkK1N|UyKM7:TR?= MkjXV2FPT0WU
ATN-1 NFfsVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJwM{OwPFIh|ryP MljyV2FPT0WU
HCC1954 NITse3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\TcnNKSzVyPUKuN|Q1ODhizszN NEnJTFRUSU6JRWK=
SCC-15 NYjISVNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PvbWlEPTB;Mj6zPVMyOiEQvF2= M4LzVnNCVkeHUh?=
COLO-668 NHH1SY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO0Znc2UUN3ME2yMlQ{OiEQvF2= M1TXd3NCVkeHUh?=
LB373-MEL-D MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfiTWM2OD1{LkW0Olc4KM7:TR?= M1;B[XNCVkeHUh?=
no-10 NGLMUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPFTWM2OD1{LkW0PVQ4KM7:TR?= MUjTRW5ITVJ?
HT-1197 M3fBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn6TWM2OD1{Lk[zNVg5KM7:TR?= NVn0VFlwW0GQR1XS
DU-145 M1zpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\iTWM2OD1{Lke5NVYzKM7:TR?= MULTRW5ITVJ?
SK-N-AS Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfxPHhQUUN3ME2yMlg1Pjl{IN88US=> MXLTRW5ITVJ?
MOLT-4 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzlTWM2OD1{Lki1N|IzKM7:TR?= MnvLV2FPT0WU
EW-22 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDSUpZKSzVyPUKuPVI5PDFizszN NGT2cVVUSU6JRWK=
DB MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\lS2lEPTB;Mj65O|c2QSEQvF2= MV7TRW5ITVJ?
HL-60 NGPEem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzJSnNKSzVyPUOuNFQ{PzZizszN MWDTRW5ITVJ?
SK-N-DZ MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTjTWM2OD1|LkC1NFc2KM7:TR?= MX7TRW5ITVJ?
NY MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTNwMEi1OFIh|ryP MWfTRW5ITVJ?
T47D NFfnXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTaUW9KSzVyPUOuNVA2PThizszN MonvV2FPT0WU
NCI-H2029 NFWwSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjET3ZvUUN3ME2zMlIzPDd5IN88US=> MY\TRW5ITVJ?
KARPAS-299 NYrHNnVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rTNGlEPTB;Mz6yOlAzPyEQvF2= NYrzOnY3W0GQR1XS
KM-H2 M4DzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTOT5hKSzVyPUOuN|A3QCEQvF2= MkXhV2FPT0WU
CHP-134 MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLrWW1UUUN3ME2zMlQ4OzlizszN NU\BRoRrW0GQR1XS
22RV1 Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH4TWM2OD1|LkS5NVY5KM7:TR?= MnrZV2FPT0WU
NB5 NGnLb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW4XYlKUUN3ME2zMlUxPjh7IN88US=> NYnaeIhTW0GQR1XS
CW-2 NY\XS4o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTTW5ZkUUN3ME2zMlU2OzF2IN88US=> NWrIWpRoW0GQR1XS
EFO-21 NVLCOlRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f5cmlEPTB;Mz61Olk1KM7:TR?= MnLqV2FPT0WU
HuH-7 MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zFdWlEPTB;Mz61PFQyPCEQvF2= NV\PcYtXW0GQR1XS
ALL-PO MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XUXmlEPTB;Mz62NlM{PSEQvF2= NYrnWGoxW0GQR1XS
EM-2 M1PjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXzR|NjUUN3ME2zMlY6ODFzIN88US=> NIPVU|BUSU6JRWK=
KLE NUXKbnp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPpTWM2OD1|LkezNFI6KM7:TR?= MVzTRW5ITVJ?
NEC8 NUP6cVkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTNwOUG4NFgh|ryP Mnj2V2FPT0WU
KP-N-YN MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\4UVhwUUN3ME2zMlk{PDd4IN88US=> NHfsSZlUSU6JRWK=
SK-MEL-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[wTWM2OD12LkCzOVE5KM7:TR?= NInBR3NUSU6JRWK=
CAL-54 M{WzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT5W5FDUUN3ME20MlA2QTFizszN MoDWV2FPT0WU
MS-1 NVnOflNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHxTWM2OD12LkG2NVU2KM7:TR?= MojwV2FPT0WU
NCI-H209 NITVNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HaXWlEPTB;ND6yPVk6QSEQvF2= M2jmPHNCVkeHUh?=
NOMO-1 M{HvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPPR4gzUUN3ME20MlMzOTNzIN88US=> NFv3XppUSU6JRWK=
RPMI-2650 MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j0bWlEPTB;ND6zOlMzPyEQvF2= MW\TRW5ITVJ?
NCI-H810 M{KyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTRwM{m3N|Yh|ryP NVi0UYxLW0GQR1XS
Ca9-22 Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTRwNEW2PVEh|ryP MXrTRW5ITVJ?
ES4 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXZfY1KSzVyPUSuOFcxQTVizszN NHf2NZhUSU6JRWK=
ES6 M4TH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXzSYpKSzVyPUSuOFk3PTdizszN NX\VSFFoW0GQR1XS
DMS-114 MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\uXWlEPTB;ND61OFY6OSEQvF2= M2[4NHNCVkeHUh?=
ONS-76 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7HSYlRUUN3ME20MlU4QTVizszN NYP0ZmpLW0GQR1XS
K-562 NV3LfFZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTRwN{O4NVQh|ryP MkXqV2FPT0WU
MHH-NB-11 NUniNmRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTRwN{W0OlEh|ryP NFPJXXJUSU6JRWK=
Calu-3 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTRwN{i1OFgh|ryP MYHTRW5ITVJ?
HT55 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTRwOES1OFUh|ryP MWPTRW5ITVJ?
SK-N-FI NEi3OItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrtdlRKSzVyPUSuPFUxODlizszN NIrTRmJUSU6JRWK=
ES1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPYTWM2OD12Lki2NFU4KM7:TR?= NGWze4RUSU6JRWK=
SF126 NUPSVoc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO1TWM2OD12LkmzNVg1KM7:TR?= MX\TRW5ITVJ?
ES5 NH7YNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHy4T3RKSzVyPUWuNVI1OjdizszN NYGz[5VoW0GQR1XS
LoVo NW\SbFBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;adGlEPTB;NT6xOVg4OSEQvF2= MVPTRW5ITVJ?
SNU-387 NUHXOnRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGyfY96UUN3ME21MlMzOzN7IN88US=> NXi2b|NYW0GQR1XS
C8166 NI\JSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjMSHY3UUN3ME21MlM3OzN7IN88US=> MUjTRW5ITVJ?
LS-1034 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSwTWM2OD13LkSyN|A4KM7:TR?= MlPvV2FPT0WU
GR-ST NXnoWXNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu3eYx5UUN3ME21MlUzOjBzIN88US=> MlXmV2FPT0WU
NCI-H1092 NWrRd|NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml31TWM2OD13LkeyPFQ{KM7:TR?= MkL0V2FPT0WU
647-V Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWSwR|FHUUN3ME21Mlc1PzB4IN88US=> MXnTRW5ITVJ?
EW-13 NUTxWmZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\5VodKSzVyPUWuO|Y3OjdizszN NXjLTppIW0GQR1XS
KGN MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTZwMEm5NlEh|ryP M3X2N3NCVkeHUh?=
D-423MG MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTZwNECyPFQh|ryP NU[xb2xUW0GQR1XS
ECC10 M2PH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1THNWlEPTB;Nz6xNFExOSEQvF2= MnLiV2FPT0WU
TE-5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r0XmlEPTB;Nz60NVI6QCEQvF2= NYKzSVJVW0GQR1XS
P12-ICHIKAWA NWfpcJFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXLWYNnUUN3ME23MlQ2PTJ|IN88US=> MnXkV2FPT0WU
NCI-H82 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTdwNEW3NFEh|ryP NFPjVpNUSU6JRWK=
NCI-H1993 M2\6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\HPJhvUUN3ME23Mlg{ODZ|IN88US=> NUfSXmhjW0GQR1XS
RH-1 NEDCcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTHSZpVUUN3ME23Mlg2OjR2IN88US=> MmLrV2FPT0WU
SW948 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TI[GlEPTB;Nz65OlA1QSEQvF2= M{mxSXNCVkeHUh?=
CAL-33 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:zWnQ{UUN3ME23Mlk6QTN6IN88US=> NFrVOYdUSU6JRWK=
U-266 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrjcGhKSzVyPUiuNVU4PzdizszN MWrTRW5ITVJ?
CAL-72 MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfmfXV7UUN3ME24MlIxOzJizszN MoDBV2FPT0WU
SNU-423 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rzemlEPTB;OT6zOlY3PiEQvF2= MoriV2FPT0WU
KG-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TNb2lEPTB;OT61PFQ2PiEQvF2= M4DHWXNCVkeHUh?=
HCC1395 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Xn[mlEPTB;OT65NlM2OiEQvF2= M33pdXNCVkeHUh?=
BE-13 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLxUVhvUUN3ME2xNE45QDl{IN88US=> M2LmNnNCVkeHUh?=
MKN7 M4qyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jFO2lEPTB;MUCuPVc3PSEQvF2= MlrrV2FPT0WU
697 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFzLkG0O|Ih|ryP MXrTRW5ITVJ?
LU-135 NH\aeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFzLkKzNFch|ryP NVXjSlZyW0GQR1XS
ES7 NH3CZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\KfmlEPTB;MUGuN|MyOyEQvF2= NXnkWpVPW0GQR1XS
SK-HEP-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XEOmlEPTB;MUGuO|Y1PiEQvF2= M4\je3NCVkeHUh?=
BEN M{O4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIiwOZdKSzVyPUGxMlg2OSEQvF2= NX7oW|V2W0GQR1XS
NCI-H1770 MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF61b|VKSzVyPUGyMlEzPiEQvF2= MWjTRW5ITVJ?
SW13 NUC2cHBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;nWGxKSzVyPUGyMlE2PDFizszN M1H6UHNCVkeHUh?=
MZ1-PC MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;yTYJKSzVyPUGyMlU1PTJizszN NIGzR5pUSU6JRWK=
Mo-T Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX21elFGUUN3ME2xNk44PDJzIN88US=> M1;0d3NCVkeHUh?=
HLE M{PzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPGW3VKSzVyPUGyMlgzOTVizszN M4j1fHNCVkeHUh?=
RCC10RGB Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDOR3RzUUN3ME2xN{43PzFizszN NFmzUlJUSU6JRWK=
COLO-320-HSR MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[xTWM2OD1zMz63N|gyKM7:TR?= M2TNN3NCVkeHUh?=
BHT-101 NI\XPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF|LkizOFUh|ryP NGHrZWdUSU6JRWK=
OCUB-M NXHmWmxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrO[XFKSzVyPUG0MlE3ODJizszN NV7pd5JyW0GQR1XS
MEG-01 Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrlTWM2OD1zND6zO|A5KM7:TR?= MY\TRW5ITVJ?
RS4-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zrdWlEPTB;MUSuO|QzKM7:TR?= NEfOdlJUSU6JRWK=
MN-60 Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j6TGlEPTB;MUSuO|g6PCEQvF2= NHL2[nNUSU6JRWK=
NCI-H1304 MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrDXGNKSzVyPUG1MlA1OjVizszN NYXCXmEzW0GQR1XS
Ramos-2G6-4C10 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf0VXJKSzVyPUG1MlA2QDFizszN MoDVV2FPT0WU
NCI-H2342 NGHQZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nUVGlEPTB;MUWuNlA1PCEQvF2= MX3TRW5ITVJ?
LAN-6 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\pOGlKSzVyPUG1MlQ1OTRizszN M1S5RXNCVkeHUh?=
JVM-2 NGjH[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoKzTWM2OD1zNT61O|Q5KM7:TR?= M4L2U3NCVkeHUh?=
P30-OHK MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OyXmlEPTB;MU[uNFYyPCEQvF2= M3TGVXNCVkeHUh?=
C-33-A NYXsVIp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF4Lk[yNVQh|ryP NFHSdHhUSU6JRWK=
RPMI-8866 NE[1XWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjPXXRKSzVyPUG2Mlg1QTZizszN MkOwV2FPT0WU
NCI-H630 NEHycYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonqTWM2OD1zNj64OVM4KM7:TR?= NYnSU2pFW0GQR1XS
KYSE-140 NXTOSJlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTF5LkKwNlgh|ryP MVPTRW5ITVJ?
T84 MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\vTWM2OD1zOD64Olk2KM7:TR?= M3HWdXNCVkeHUh?=
KU-19-19 NEftXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PpcGlEPTB;MUiuPVYxQCEQvF2= NXzpSpA6W0GQR1XS
BALL-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjWTZBbUUN3ME2xPU4{Ozl7IN88US=> MU\TRW5ITVJ?
Calu-6 M{fqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH2T4dKSzVyPUG5MlQ6OiEQvF2= MU\TRW5ITVJ?
EGI-1 NW\jWnk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD0W3QzUUN3ME2xPU42QThizszN MlzkV2FPT0WU
MFH-ino NYLme5o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDLd5pKSzVyPUG5Mlc1PTRizszN M2npZ3NCVkeHUh?=
GB-1 NHnEWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJyLkO1N|Uh|ryP NY[2dm91W0GQR1XS
NCI-H1693 MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq0TXU2UUN3ME2yNE43PTB3IN88US=> M3nyNXNCVkeHUh?=
SW1116 M4LFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC5PXRGUUN3ME2yNE46OzZ{IN88US=> M3TtWnNCVkeHUh?=
H-EMC-SS MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXnTWM2OD1{Mj6wOFUh|ryP MYfTRW5ITVJ?
D-502MG Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;EUHBKSzVyPUKyMlgzPjFizszN MYnTRW5ITVJ?
IA-LM M4rYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TqdWlEPTB;MkOuNlQ6OyEQvF2= M1LXbnNCVkeHUh?=
SW1463 NGnzTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJ|Lke5JO69VQ>? MWTTRW5ITVJ?
JAR NXm0bGczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULHZoxuUUN3ME2yOE4{Ojl|IN88US=> NUfGO|FVW0GQR1XS
HT MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjHe5ltUUN3ME2yOE41PzV|IN88US=> MofMV2FPT0WU
LCLC-103H NXvL[YRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzQSFZKSzVyPUK0Mlg1PDlizszN Mn:5V2FPT0WU
SNU-449 Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJ2Lki3OFEh|ryP MlzzV2FPT0WU
KE-37 NGnTXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXlRYxHUUN3ME2yOU4xQTJ6IN88US=> NXPze2d[W0GQR1XS
NCI-H1623 NGfBfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHEN|RKSzVyPUK3MlE{ODNizszN NUfHenJJW0GQR1XS
MOLT-13 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJ5LkO1NVYh|ryP NHPqS5FUSU6JRWK=
COLO-741 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHKUYdWUUN3ME2zNU4{OzN|IN88US=> NUPmbphSW0GQR1XS
NB6 NI\Ne|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX0eZhRUUN3ME2zNk4zQDd4IN88US=> MYDTRW5ITVJ?
MOLT-16 NUXHSI9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPKO|BTUUN3ME2zN{4xODV3IN88US=> MUPTRW5ITVJ?
IST-MES1 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN2LkC1OFEh|ryP MUfTRW5ITVJ?
A4-Fuk M1f6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET2WJFKSzVyPUO1MlA3PiEQvF2= MmTnV2FPT0WU
CAL-85-1 NFXKTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoO5TWM2OD1|NT6yPFE4KM7:TR?= MoTCV2FPT0WU
CCRF-CEM MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITzfYFKSzVyPUO3MlE2OzZizszN MkjFV2FPT0WU
HAL-01 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37TPGlEPTB;M{iuOFg5QSEQvF2= M1nOdXNCVkeHUh?=
HEL MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PkVmlEPTB;NEOuN|QxQSEQvF2= NEXrW|VUSU6JRWK=
EW-1 NGiwNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W5U2lEPTB;NEOuOFc3QCEQvF2= NHnPfoZUSU6JRWK=
MDA-MB-231 M2D6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTR3LkGxPVkh|ryP MlzEV2FPT0WU
ABC-1 NYjYfGRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzUfVlKSzVyPUS2Mlg2OzhizszN M2qzSnNCVkeHUh?=
NCI-H446 NEPlenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Owc2lEPTB;NEiuOVA2QCEQvF2= NVH4bpc5W0GQR1XS
MHH-PREB-1 NGH0e4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmGwTWM2OD12OT62NFA4KM7:TR?= NVi1NodtW0GQR1XS
DOHH-2 NFTDS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULZV2sxUUN3ME20PU43PjV4IN88US=> NGDpemNUSU6JRWK=
GCT MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfETWM2OD12OT62PVc3KM7:TR?= MWXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; 

PubMed: 20090920     


Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control.

EGFR / PDGFR / AKT / MAPK / c-RAS; 

PubMed: 18682579     


17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment.

pAKT / pMAPK / pRb; 

PubMed: 18682579     


The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment.

Cleaved PARP / Survivin; 

PubMed: 18827603     


Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control.

LATS1 / p-LATS1 / YAP / CTGF; 

PubMed: 25712415     


Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF.  The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.

20090920 18682579 18827603 25712415
Immunofluorescence
STAT3; 

PubMed: 27279418     


Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole.

YAP / TAZ; 

PubMed: 25290150     


Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM).

β-catenin / E-cadherin; 

PubMed: 25290150     


Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.

27279418 25290150
Growth inhibition assay
Cell viability; 

PubMed: 18682579     


17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.

18682579
In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
+ Expand

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
+ Expand
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Ethanol 5 mg/mL (8.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+corn oil
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
in solvent
Synonyms CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00103272 Terminated Drug: tanespimycin|Drug: bortezomib Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00098488 Terminated Drug: tanespimycin|Biological: rituximab B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00118248 Completed Drug: tanespimycin Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma National Cancer Institute (NCI) December 2004 Phase 2
NCT00098423 Completed Drug: tanespimycin|Drug: cytarabine Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes National Cancer Institute (NCI) November 2004 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID